- Home
- GROY vs ACRV Comparison
GROY vs ACRV Comparison
Compare GROY & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROY
- ACRV
- Stock Information
- Founded
- GROY 2020
- ACRV 2018
- Country
- GROY Canada
- ACRV United States
- Employees
- GROY N/A
- ACRV N/A
- Industry
- GROY
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- GROY
- ACRV Health Care
- Exchange
- GROY Nasdaq
- ACRV Nasdaq
- Market Cap
- GROY 206.6M
- ACRV 189.0M
- IPO Year
- GROY 2021
- ACRV 2022
- Fundamental
- Price
- GROY $1.41
- ACRV $5.54
- Analyst Decision
- GROY Strong Buy
- ACRV Strong Buy
- Analyst Count
- GROY 4
- ACRV 6
- Target Price
- GROY $3.31
- ACRV $22.40
- AVG Volume (30 Days)
- GROY 1.1M
- ACRV 69.3K
- Earning Date
- GROY 03-19-2025
- ACRV 03-27-2025
- Dividend Yield
- GROY N/A
- ACRV N/A
- EPS Growth
- GROY N/A
- ACRV N/A
- EPS
- GROY N/A
- ACRV N/A
- Revenue
- GROY $7,764,000.00
- ACRV N/A
- Revenue This Year
- GROY $270.34
- ACRV N/A
- Revenue Next Year
- GROY $119.32
- ACRV N/A
- P/E Ratio
- GROY N/A
- ACRV N/A
- Revenue Growth
- GROY 197.02
- ACRV N/A
- 52 Week Low
- GROY $1.16
- ACRV $3.83
- 52 Week High
- GROY $2.21
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- GROY 54.53
- ACRV 47.59
- Support Level
- GROY $1.40
- ACRV $5.00
- Resistance Level
- GROY $1.49
- ACRV $6.08
- Average True Range (ATR)
- GROY 0.07
- ACRV 0.64
- MACD
- GROY -0.00
- ACRV 0.01
- Stochastic Oscillator
- GROY 47.83
- ACRV 25.68
About GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and streaming company. It offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.